RecallDepth
Class II Ongoing

Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO Pharma Inc., Madison, NJ 07940, USA,

This recall is currently active, issued March 4, 2026. It was issued by Leo Pharma Inc.

Company
Leo Pharma Inc
Recall Initiated
February 10, 2026
Posted
March 4, 2026
Recall Number
D-0339-2026
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
11,407 units
Firm Location
Madison, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.

Distribution

Nationwide in the USA

Lot / Code Info

Lot: a) 003E24C, Exp 04/30/2027; b) 003E24A, Exp 04/30/2027.

More recalls by Leo Pharma Inc

View all recalls by this company →

Other recent Class II Drug recalls